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Stem cells can self-renew and differentiate into multiple cell types. These characteristics are maintained by the
combination of specific signaling pathways and transcription factors that cooperate to establish a unique epigenetic
state. Despite the broad interest of these mechanisms, the precise molecular controls by which extracellular signals
organize epigenetic marks to confer multipotency remain to be uncovered. Here, we use human embryonic stem
cells (hESCs) to show that the Activin–SMAD2/3 signaling pathway cooperates with the core pluripotency factor
NANOG to recruit the DPY30-COMPASS histone modifiers onto key developmental genes. Functional studies
demonstrate the importance of these interactions for correct histone 3 Lys4 trimethylation and also self-renewal and
differentiation. Finally, genetic studies in mice show that Dpy30 is also necessary to maintain pluripotency in the
pregastrulation embryo, thereby confirming the existence of similar regulations in vivo during early embryonic
development. Our results reveal the mechanisms by which extracellular factors coordinate chromatin status and
cell fate decisions in hESCs.
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Stem cells are defined by their ability to propagate indefi-
nitely while retaining the capacity to differentiate into
multiple cell types. Such remarkable characteristics are
dictated by specific cellular signaling pathways, transcrip-
tional networks, and epigenetic regulators. These ele-
ments ultimately direct stem cell fate decisions and
thus are essential to generate cells required for not only
embryonic development but also adult tissue homeostasis
and repair (Blanpain and Fuchs 2009; Young 2011; Clevers
2013). Human pluripotent stem cells (hPSCs) isolated
from an embryo at the blastocyst stage (human embryonic
stem cells [hESCs]) or obtained from reprogrammed
somatic cells (human induced pluripotent stem cells
[hIPSCs]) represent an advantageous model to study these
regulations at the molecular level. Indeed, hPSCs can
grow indefinitely in vitro while preserving their ability
to differentiate into the three primary germ layers: neuro-
ectoderm, mesoderm, and endoderm.
The signaling pathways controlling hPSC cell fate are
relatively well known, and the TGFβ superfamily has a
central function in thesemechanisms (Xu et al. 2008; Val-
lier et al. 2009b,c). In particular, Activin/Nodal signaling
and its effector, SMAD2/3, are essential to maintain plu-
ripotency, inhibit neuroectoderm specification, and drive
mesendoderm differentiation (Vallier et al. 2005; Brown
et al. 2011). Activin–SMAD2/3 can achieve this broad
range of functions by interacting with tissue-specific mas-
ter regulators of cell fate that direct SMAD2/3 to subsets
of genomic regulatory domains in a cell-type specific fash-
ion (Mullen et al. 2011). As such, SMAD2/3 cooperates
withNANOG in hPSCs tomaintain the core pluripotency
transcriptional network while interacting with EOMES
during mesendoderm differentiation to activate the
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transcription of master developmental regulators (Vallier
et al. 2009a; Teo et al. 2011). However, the mechanism
by which SMAD2/3 controls the transcriptional activity
of its key target genes in hPSCs remains unknown, and
it is especially unclear whether this transcriptional con-
trol involves epigenetic mechanisms.
Indeed, hPSCs differ from somatic cells due to a spe-
cific epigenetic state characterized by a highly dynamic
and accessible chromatin structure, which is lost upon
induction of differentiation. This epigenetic landscape
includes numerous genes that are simultaneouslymarked
by trimethylation of histone 3 Lys4 (H3K4me3) and
H3K27me3, two histone marks that are usually found
on active and inactive genes, respectively, and thus are as-
sociatedwith opposite transcriptional activities (Pan et al.
2007). Consequently, “bivalent” H3K4me3–H3K27me3
marks have been proposed to poise developmental genes
for rapid activation or silencing upon differentiation
(Bernstein et al. 2006). H3K4me3 is deposited by COM-
PASS complexes, which contain enzymes of the MLL/
SETD1 family of histone methyltransferases, while
H3K27me3 is imposed by the Polycomb group proteins
(Schuettengruber et al. 2007).
Despite the wealth of studies describing the dynamic
changes of chromatin histone marks in pluripotent cells
and their derivatives, there are several important unan-
swered questions. First, whether and how extracellular
signaling cues control the H3K4me3 and H3K27me3
epigenetic landscape remain to be uncovered. Second,
H3K4me3 andH3K27me3marks could have a direct func-
tional importance in the transcriptional regulation of
genes directing cell fate decisions or could be just a con-
sequence of such regulations (Vastenhouw and Schier
2012; Voigt et al. 2013). Finally, studies of H3K4me3 and
H3K27me3 function in pluripotency have been performed
in mouse ESCs (mESCs), which represent a different plu-
ripotent state than hPSCs (Brons et al. 2007). Overall,
the regulation and function of H3K4me3 and H3K27me3
in human pluripotency still need to be elucidated.
Considering the central role of Activin/Nodal signaling
in pluripotency, we decided to explore its possible func-
tion in the regulation of H3K4me3 and H3K27me3 in
hESCs. For that, we performed detailed gene expression
profile experiments combined with H3K4me3 and
H3K27me3 ChIP-seq (chromatin immunoprecipitation
[ChIP] followed by deep sequencing) on hESCs grown in
the absence of Activin/Nodal signaling. These experi-
ments showed that inhibition of Activin/Nodal results
in a rapid loss of H3K4me3 (but not H3K27me3) on a spe-
cific subset of genomic regions associated to master regu-
lators of pluripotency and mesendoderm specification
that are subsequently silenced, thus leading to neuroecto-
derm differentiation. Activin/Nodal signaling achieves
this regulation through its effector, SMAD2/3, which co-
operates with NANOG to recruit DPY30, a subunit of
the COMPASS methyltransferase complexes, on key
developmental regulators. Importantly, the relevance of
these mechanisms was demonstrated by loss-of-function
experiments showing that DPY30 is essential for pluripo-
tency and mesendoderm specification of hESCs. Finally,
we demonstrated the importance of our findings in the
context of embryonic development by showing that the
absence of Dpy30 in the mouse embryo impairs gastrula-
tion of the pluripotent epiblast, thus blocking mesendo-
derm specification while promoting neuroectoderm
differentiation. Taken together, our results identify the
fundamental dynamics by which signaling pathways or-
chestrate transcriptional responses via epigenetic changes
to establish the capacity of stem cells to differentiate into
specific lineages.
Results
Activin/Nodal signaling is necessary to maintain
the H3K4me3 mark on a specific subset of genes
characterizing the pluripotent state of hESCs
In order to define the function of Activin/Nodal signaling
in the control of the epigenetic status of hESCs, we inves-
tigated the effect of SB431542 (SB), an antagonist of the
ALK4 and ALK7 type I Activin/Nodal receptors (Fig.
1A), on the deposition of H3K4me3 and H3K27me3 his-
tone marks. Preliminary experiments showed that 2 h of
SB treatment of hESCs was the shortest time required
to fully block SMAD2/3 phosphorylation and abolish
binding to its genomic targets (Fig. 1B; data not shown).
Therefore, we performed ChIP-seq for both H3K4me3
and H3K27me3 after 2 h of SB treatment in order to cap-
ture the more immediate and hence more likely direct ef-
fects of Activin/Nodal inhibition (Fig. 1A; Supplemental
Table S1). We found that 491 out of 27,922 H3K4me3
peaks showed a significant decrease after 2 h of SB (fold
change≤−1.5; Benjamini-Hochberg false discovery rate
[FDR] adjusted P≤ 1 × 10−3), while only 14 were up-regu-
lated (Fig. 1C; Supplemental Table S1). Importantly, de-
creased H3K4me3 regions were significantly associated
with genes involved in Activin/Nodal signaling and
were expressed in the epiblast and endoderm (GREAT
analysis) (Supplemental Fig. S1A; Supplemental Table
S1). In contrast, we observed almost no significant differ-
ences for the 11,347 H3K27me3 peaks identified, with
only one region being increased, and none showing a
decrease (Fig. 1C). Thus, Activin/Nodal signaling is neces-
sary formaintaining the positiveH3K4me3 histonemarks
on a subset of genes in hESCs, while the deposition of the
negative H3K27me3 histone mark appears to be indepen-
dent of Activin/Nodal.
According to the known typical localization of
H3K4me3 (Calo and Wysocka 2013), several of the
H3K4me3 peaks that decreased after SB treatment
marked proximal promoters and gene transcription start
sites (Fig. 1D). These included several known Activin/
Nodal target genes such as NANOG, POU5F1/OCT4,
LEFTY1, and NODAL (Fig. 1E). Interestingly, H3K4me3
was decreased on key pluripotency regulators that are
highly expressed and marked by H3K4me3 but not
H3K27me3, such as NANOG, POU5F1/OCT4, DPPA4,
GDF3, and PRDM14 (Young 2011). However, we observed
that inhibition of Activin/Nodal signaling also resulted in
impaired H3K4me3 of many genes that only show
Activin/Nodal controls H3K4me3 in hESCs
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background expression in hESCs (see Supplemental Fig.
S2A for gene expression data) and are marked by both
H3K4me3 and H3K27me3, such as LEFTY1, NODAL,
LEFTY2,CER1,WNT3, and FGF8. Indeed, 25% of the pro-
moters where H3K4me3 was decreased after 2 h of SB dis-
played such bivalent marking (Fig. 1F), representing a
proportion similar to that of the overall abundance of
these elements (32%) (Fig. 1F). Remarkably, the bivalent
promoters where H3K4me3 was decreased after SB were
associated with genes expressed in the primitive streak,
mesoderm, and endoderm (Supplemental Fig. S1B; Sup-
plemental Table S1; Tam and Loebel 2007), thereby sup-
porting the proposed role of bivalent marks in the
priming of developmental gene expression (Bernstein
et al. 2006). Aside from promoter-associated regions, we
observed that ∼60% of H3K4me3 peaks that were down-
regulated after 2 h of SB fell outside of gene bodies (Fig.
1D). Inspection of these regions revealed a frequent associ-
ationwith the deposition of H3K4me1 andH3K27ac (Sup-
plemental Fig. S1C), two well-established markers of
active enhancers (Calo and Wysocka 2013). Indeed, 25%
of intergenic H3K4me3 peaks that decreased after 2 h of
SB shared this particular feature (Fig. 1G). In contrast,
only 0.02% of them colocalized with H3K4me1 and
H3K27me3, a chromatin signature that identifies poised
enhancers (Rada-Iglesias et al. 2011), while the overall
abundance of such regions was much higher (18%) (Fig.
1G). As such, Activin/Nodal signaling appears to regulate
H3K4me3 specifically on active distal enhancers but not
on poised ones.
Importantly, inhibition of Activin/Nodal signaling for
2 h specifically impaired H3K4me3 but not H3K4me2
or H3K4me1 levels on both promoter and enhancer re-
gions (Supplemental Fig. S1D). Indeed, H3K4me2 and
H3K4me1 levels were either unchanged or increased on
most of the regions that we analyzed, with the only ex-
ception being LEFTY1, where both H3K4me3 and
H3K4me2 levels were decreased. Moreover, histone 3 en-
richment was unaffected by inhibition of Activin/Nodal
signaling (Supplemental Fig. S1D), demonstrating that
the observed reduction of H3K4me3 levels was not due
to nucleosome repositioning. Overall, these results
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Figure 1. Activin/Nodal regulates H3K4me3 of a subset of genes in hESCs. (A) Schematic of the experimental approach. (B) ChIP-qPCR
for SMAD2/3 on its binding sites associated to the indicated genes (see also E) before and after inhibition of Activin/Nodal with SB for 2
h. (C ) Results of the statistical analysis of ChIP-seq data. (D) Annotation of H3K4me3 peaks to genomic features. (E) ChIP-seq results
for H3K4me3 and H3K27me3 on selected SMAD2/3 target genes before and after inhibition of Activin/Nodal with SB for 2 h. Lines rep-
resent read enrichments normalized by million mapped reads and the size of the library. SMAD2/3-binding sites in hESCs are reported
(Brown et al. 2011). (F ) Colocalization of H3K27me3 peakswithH3K4me3 peaks centered in a range of ±5 kb from the closest transcription
start site (promoters). (G) Colocalization ofH3K4me1 andH3K27ac peakswithH3K4me3 peaks centered outside a range of ±5 kb from the
closest transcription start site (intergenic).
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suggest that inhibition of Activin/Nodal results in specif-
ic H3K4me3 demethylation.
Interestingly, 21 of the 491 H3K4me3 peaks that de-
creased upon Activin/Nodal signaling inhibition directly
overlapped with SMAD2/3-binding sites (P < 1 × 10−4 as
measured by genomic association test [GAT]). Among
others, canonical SMAD2/3 target genes such as
NANOG, POU5F1/OCT4,NODAL, and LEFTY1 showed
this association (Fig. 1E), and, indeed, a decrease of
H3K4me3 after 2 h of SB on such regions correlated with
loss of SMAD2/3 binding (Fig. 1B). Moreover, regions
with decreased H3K4me3 after Activin/Nodal inhibition
were significantly associatedwith nearby SMAD2/3-bind-
ing sites (27% and 100% were, respectively, 10 kb or 100
kb upstream of/downstream from the closest SMAD2/3-
binding site; GAT, P < 1 × 10−4 and P < 0.033, respective-
ly). This observation is in agreementwith previous reports
that showed how SMAD2/3 regulates the expression of its
target genes mostly by binding to distal enhancers rather
than proximal promoters (Brown et al. 2011; Kim et al.
2011).
Taken together, these data suggest that Activin/
Nodal signaling could control the expression of mas-
ter regulators of both pluripotency and germ layer specifi-
cation by maintaining H3K4me3 on both gene promoters
and intergenic enhancers.
Activin/Nodal signaling maintains H3K4me3 histone
marks that are functionally important for pluripotency
and cell fate decisions
To test the functional relevance of H3K4me3 loss after SB
treatment, we investigated the transcriptional dynamics
resulting from both acute and chronic Activin/Nodal sig-
naling inhibition. Accordingly, we performed gene expres-
sion microarrays of hESCs grown in the presence of
Activin or SB for 2 h, 4 h, 8 h, 24 h, and 48 h (Fig. 2A; Sup-
plemental Table S2). Hierarchical clustering of differen-
tially expressed probes across the time course (top 10%
of probes ranked by their Hotelling T2 statistic from the
timecourse R package) identified three main clusters,
two of them containing genes whose expression was de-
creased after inhibition of Activin/Nodal (Fig. 2B,C). As
expected, these clusters were significantly enriched in
genes associated with TGFβ signaling, regulation of cell
differentiation, and cell cycle (gene enrichment analysis)
(Fig. 2C; Supplemental Table S2). However, these two
clusters differed in both their relative size and the dynam-
ics of the transcriptional inhibition: The first smaller clus-
ter started to decrease in expression already after 2 h,
while the second bigger cluster was significantly affected
only after 24 h. Importantly, both clusters presented sig-
nificant overlap with genes bound by SMAD2/3 (70 out
of 233 for cluster 1 and 444 out of 1819 for cluster 2, hyper-
geometric test P = 1.88 × 10−11 and P = 7.09 × 10−40, re-
spectively; SMAD2/3-bound genes from Brown et al.
2011) and contained several well-known SMAD2/3 direct
targets such as LEFTY1, NODAL, NANOG, SOX17,
EOMES, and GSC (cluster 1) and POU5F1/OCT4,
DPPA4, and EPCAM (cluster 2). Importantly, these two
clusters included not only several pluripotency factors
but also regulators of mesendoderm differentiation (like
LEFTY1,NODAL, SOX17, EOMES, andGSC) that are ex-
pressed at background levels in hESCs (Supplemental Fig.
S2A reports the Ct values for such genes), in agreement
with the known “primed” pluripotency status of hESCs
(Nichols and Smith 2009). As such, Activin/Nodal inhibi-
tion not only reduces expression of pluripotency genes
but also abolishes the primed expression of mesendoderm
regulators. Conversely, a third major cluster represented
transcripts induced after 24–48 h of Activin/Nodal in-
hibition (Fig. 2B,C). This was significantly enriched in
genes involved in neural development and contained sev-
eral known SMAD2/3-inhibited factors such as CDX2,
WNT8A, EGFLAM,MEIS2, and CITED2 (Fig. 2C; Supple-
mental Table S2). Importantly, quantitative PCR (qPCR)
experiments on a subset of genes from each of these three
clusters validated the accuracy of the microarray analyses
(Supplemental Fig. S2A). Overall, these observations
showed that inhibition of Activin/Nodal signaling leads
to both rapid and delayed transcriptional responses that
regulate expression of genes involved in pluripotency
and cell fate decisions.
We next investigated the relationship between
H3K4me3 mark reduction and the transcriptional effects
induced by Activin/Nodal inhibition. Interestingly, 108
out of 415 genes associated to decreased H3K4me3 after 2
h of SBwere among the top 10%of differentially expressed
genes across the kinetics of Activin/Nodal inhibition
(Supplemental Table S2). These included several genes
crucially required for pluripotency (such as NANOG,
POU5F1/OCT4, DPPA4, GDF3, and PRDM14) as well
as regulators of mesendoderm differentiation (such as
LEFTY1, LEFTY2, NODAL, CER1, WNT3, and FGF8).
These genes belonged to either cluster 1 or cluster 2 de-
scribed above and were transcriptionally repressed upon
inhibition of Activin/Nodal signaling (Fig. 2D), in agree-
ment with the known role of H3K4me3 as a histone
mark that promotes gene expression (Ruthenburg et al.
2007). Gene set enrichment analysis (GSEA) confirmed
thatgenesdown-regulatedafter inhibitionofActivin/Nod-
al for 48 h were significantly associated with regions in
which H3K4me3 was reduced after 2 h of SB (Fig. 2E). Of
note, a transcriptional decrease in genes showing reduced
H3K4me3after2hofSBoccurredprogressivelyandreached
the highest significance at 48 h (Fig. 2F; Supplemental
Fig. S2B), suggesting that changes in the H3K4me3 mark
preceded the decrease in gene expression. Thus, Activin/
Nodal signaling could maintain the expression of key
developmental regulators by controlling the deposition
of H3K4me3 on the corresponding genomic regions.
In order to confirm and extend this observation, we
monitored the levels of H3K4me3 and H3K27me3 by
ChIP-qPCR after 2 h, 4 h, and 8 h of SB treatment on a
panel of genes transcriptionally down-regulated or up-
regulated after inhibition of Activin/Nodal. Strikingly,
H3K4me3 was impaired already after 2 h of SB on both
quickly (cluster 1) or slowly (cluster 2) transcriptionally
down-regulated genes, while up-regulated ones (cluster 3)
Activin/Nodal controls H3K4me3 in hESCs
GENES & DEVELOPMENT 705
 Cold Spring Harbor Laboratory Press on May 21, 2015 - Published by genesdev.cshlp.orgDownloaded from 
were not affected (Supplemental Fig. S2C). Interestingly,
none of the genes analyzed showed any significant change
in the levels of H3K27me3 (Supplemental Fig. S2D).
These observations confirmed that loss of H3K4me3 asso-
ciated with SMAD2/3 disappearance precedes transcrip-
tional impairment on a subset of genomics targets. This
suggests a functional importance of H3K4me3 histone
mark regulation downstream from Activin/Nodal signal-
ing to maintain the expression of a core network of genes
controlling pluripotency and differentiation potency.
SMAD2/3 interacts with DPY30 to maintain H3K4me3
marks on pluripotency and mesendoderm genes
Having defined the importance of Activin/Nodal signal-
ing in maintaining H3K4me3 on key regulatory genes,
we sought to understand the underlying molecular mech-
anism. The association between decreased H3K4me3 and
SMAD2/3-binding sites suggested that Activin/Nodal sig-
naling effectors could be directly involved in the deposi-
tion of H3K4me3. Thus, we decided to test whether
Figure 2. Dynamics of the transcriptional response to Activin/Nodal inhibition and their relationshipwith epigenetic changes. (A) Sche-
matics of theexperimental approach. (B) Euclideanhierarchical clusteringof differentiallyexpressedmicroarrayprobes across a timecourse
of Activin/Nodal inhibition in hESCs (top 10% ranked byHotellingT2 statistic).Z-scores indicate the differential expressionmeasured in
numberof standarddeviations from the average level across all the timepoints.The threemajor probe clusters are indicated. (C ) Expression
profiles of probes in the clusters indicated in B. Selected results of gene enrichment analysis and representative genes for each cluster are
reported (Supplemental Table S2 contains the complete set of results). (D) As in B, but only selected representative genes that showed de-
creasedH3K4me3upon 2 h of inhibition of Activin/Nodal signaling are reported. (E) Gene set enrichment analysis (GSEA) for geneswhose
expressionwas decreased after 48hof SB in the list ofH3K4me3-associated genes ranked by thedifferentialH3K4me3enrichment before or
after 2hof SB. (F ) Expressionof thegenes closest to theH3K4me3peaksdecreasedafter 2hof SB.Theblue lines indicatenoexpressionchan-
ge. The significance of expression differences after 2 h or 48 h of SB treatment versusActivin as calculated byDunn’smultiple comparisons
tests is shown (see Supplemental Fig. S2B for results for other time points).
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SMAD2/3 could interact with the COMPASS complexes,
which are responsible for the deposition of this histone
modification. The COMPASS H3K4 methyltransferases
belong to the MLL/SETD1 family and form six func-
tional complexes classified into three subgroups, all of
which include common WRAD (WDR5, RBBP5, ASHL2,
and DPY30) cofactors (Ruthenburg et al. 2007; Ernst and
Vakoc 2012). Among the enzymes, SETD1A, MLL1/
KMT2A, and MLL2/KMT2B have the highest expression
in hESCs (data not shown), and coimmunoprecipitation
experiments revealed that SMAD2/3 bound to SETD1A
and MLL2/KMT2B, but not MLL1/KMT2A, in hESCs
(Fig. 3A).
In order to evaluate the functional relevance of such
interactions in the context of Activin/Nodal-dependent
H3K4me3marksandgeneexpression,wedecidedtoknock
down the expression of the common COMPASS cofactor
DPY30. Indeed, DPY30 is required for efficient COM-
PASS-dependent H3K4me3 but not H3K4 mono- and
dimethylation, in contrast with the other members of the
WRAD module, which are also important for H3K4me2
and H3K4me1 deposition (Ernst and Vakoc 2012). More-
over, since it is amember of all of theCOMPASS complex-
es, impairment of DPY30 should prevent compensatory
mechanisms between catalytic subunits as previously re-
ported (Jiang et al. 2011). As such, knockdown of DPY30
has been used as a powerful genetic tool to specifically im-
pairH3K4me3deposition in different cell types (Jiang et al.
2011; Yang et al. 2014), since specific inhibitors of this his-
tonemodification are not currently available. hESCs were
stably transfected with vectors expressing shRNAs direct-
ed against DPY30 (Supplemental Fig. S3A), and individual
sublinesshowing impaired levelsofDPY30attheRNAand
protein levels were isolated and expanded for further anal-
yses (Fig. 3B; Supplemental Fig. S3B). Of note, all of the re-
sults described below were confirmed with two separate
shRNAs to exclude off-target effects. Interestingly, we ob-
tained a reduced number of sublines after transfection of
DPY30 shRNAs when compared with hESCs transfected
with a vector expressing a scramble (SCR) shRNA (Supple-
mental Fig. S3C). This suggested that the absence of
DPY30 expression might not be compatible with the self-
renewal of hESCs.Accordingly, expansionof hESCsubline
knockdown for DPY30 (DPY30 knockdown hESCs) was
challenging due to a markedly increased background of
differentiation and a slower proliferation rate (Fig. 3C; Sup-
plemental Fig. S3D). Interestingly, apoptosis was not in-
creased in these cells, suggesting that DPY30 was not
required for hESC survival (Supplemental Fig. S3E). More
importantly, DPY30 knockdown hESCs displayed a re-
duced alkaline phosphatase activity (Supplemental Fig.
S3F) and a reduced expression of pluripotency and endo-
derm markers, with a parallel increase in neuroectoderm
genes (Fig. 3D).These resultswereconfirmedat theprotein
level by Western blot, flow cytometry, and immunostain-
ing (Fig. 3E;SupplementalFig. S3G,H).Therefore, theseob-
servations indicated that DPY30 is necessary to preserve
the pluripotent state of hESCs by maintaining the expres-
sion of pluripotency markers and blocking the expression
of neuroectoderm genes.
Interestingly, the phenotype of DPY30 knockdown
hESCs closely resembled the effect of Activin/Nodal sig-
naling inhibition (Smith et al. 2008). This similarity was
confirmedat a global level bymicroarrayanalyses showing
that genes down-regulated after DPY30 knockdown were
significantly associated with TGFβ signaling and signifi-
cantly overrepresented for genes required for embryonic
development, while up-regulated transcripts were over-
represented for those involved in craniofacial and neural
development (gene enrichment analysis) (Supplemental
Table S3). Moreover, the transcriptional profile of DPY30
knockdown hESCs had a highly significant overlap with
the one resulting from both 2 h (data not shown) and 48
h (Fig. 3F) of SB treatment (highest hypergeometric test
P < 1 × 10−500, as calculatedusing rank–rankhypergeomet-
ric overlap [RRHO] analysis). Indeed, all of the genes that
we validated by qPCR to be increased or decreased during
SB treatment (Supplemental Fig. S2A) followed the same
trend in DPY30 knockdown cells, including well-known
SMAD2/3 targets such as LEFTY1, NODAL, NANOG,
POU5F1/OCT4, CDX2, and WNT8A (Fig. 3G; Supple-
mental Table S3). Together, these data suggested a direct
functional interaction between DPY30 and the Activin/
Nodal–SMAD2/3 signaling pathway.
We then evaluated whether the transcriptional effects
associated with diminished DPY30 expression correlated
with changes inH3K4me3 levels. ChIP-qPCRon both plu-
ripotency and endoderm regulators activated by SMAD2/
3 and down-regulated after DPY30 knockdown showed re-
duced levels of H3K4me3 (Supplemental Fig. S3I). Inter-
estingly, DPY30 knockdown did not affect H3K4me3 on
a diversity of loci, including housekeeping genes such as
GAPDH (Supplemental Fig. S3I), thereby suggesting that
the requirement for high levels of DPY30 in hESCs is
gene-specific. Transient transfection for 48 h of a DPY30
shRNA also resulted in a similar gene-specific reduction
of H3K4me3 on SMAD2/3 target genes (Fig. 3H), indicat-
ing that histone marks quickly decreased after DPY30
knockdown. This event preceded changes in gene ex-
pression (Supplemental Fig. S3J), further supporting the
notion that this epigenetic change induced transcrip-
tional impairment. Collectively, these findings suggest
that DPY30 and SMAD2/3 cooperate to preserve the
H3K4me3 histone mark on several crucial Activin/Nodal
signaling target genes and that this mechanism is neces-
sary to maintain pluripotency of hESCs.
Mesendoderm differentiation potency of hESCs
relies on H3K4me3 deposition
Considering the effect of DPY30 knockdown in undiffer-
entiated hESCs, we decided to assess the capacity of dif-
ferentiation of DPY30 knockdown hESCs by performing
in vivo teratoma assays (Supplemental Fig. S4A). Striking-
ly, teratomas derived from DPY30 knockdown hESCs
were small and failed to completely invade the testicular
capsule of immuno-deficient mice, in contrast to those
grown from SCR shRNA control hESCs (Fig. 4A; Supple-
mental Fig. S4B). Moreover, the resulting tissue was com-
posed of only neuroectodermal lineages, such as
Activin/Nodal controls H3K4me3 in hESCs
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epithelial and neuroepithelial cells, but lacked mesoderm
and endoderm derivatives (Fig. 4A; Supplemental Fig.
S4B). These results showed that a decrease in DPY30 ex-
pression limited the capacity of hESCs to both self-renew
and differentiate into all derivatives of the three germ
layers.
To precisely characterize this differentiation potency
defect, DPY30 knockdown hESCs were grown in
A B C
E
F
H
G
D
Figure 3. DPY30 is required for H3K4me3 and expression of SMAD2/3 target genes. (A) Western blots of SMAD2/3 or control (IgG) im-
munoprecipitations (IP) from nuclear extracts of hESCs. Input is 5% of the material used for immunoprecipitation. (B) Western blots in
stable DPY30 knockdown (KD) hESC lines or controls (cells expressing a scramble [SCR] shRNA). (C ) Phase-contrast images of the same
DPY30 knockdown or control hESC colonies after the indicated number of days from the cell split (day 0). Bars, 200 μm. (D) Gene expres-
sion qPCR in DPY30 knockdown or control hESCs. Note that SOX2 is both a pluripotency and a neuroectoderm marker. For each gene,
significant differences versus both SCR sh1 and SCR sh2 (only the highest P-value is shown) as calculated by one-way ANOVA are report-
ed. (E) Immunofluorescences for the indicated proteins (green) or nuclear staining (DAPI, blue) in DPY30 knockdown or control hESCs.
Bars, 100 μm. (F ) Rank–rank hypergeometric overlap analysis (RRHO) for genes ranked by their differential expression after DPY30 knock-
down or inhibition of Activin/Nodal for 48 hwith SB. Color-coded log10 P-values indicate the significance of the overlap between genes in
the two conditions, considering hypergeometric tests. (G) Heat map showing changes in gene expression of selected SMAD2/3 target
genes after DPY30 knockdown or 48 h of SB. Z-scores were separately calculated for each experiment. (H) ChIP-qPCR for H3K4me3
on SMAD2/3 target genes in hESCs transiently transfected for 48 h with a DPY30 shRNA or a control shRNA. For each gene, significant
differences versus SCR as calculated by t-test are reported.
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chemically defined culture conditions directing differen-
tiation toward endoderm and neuroectoderm (Supple-
mental Fig. S4C; Vallier et al. 2009b). qPCR analyses for
the expression of lineage-specific markers proved that
DPY30 knockdown hESCs responded poorly to endoderm
differentiation, while neuroectoderm specification was
more efficient (Fig. 4B; Supplemental Fig. S4D). Impor-
tantly, reducedmRNA levels for endoderm genes correlat-
ed with impaired RNA polymerase II and Mediator
recruitment on their transcription start sites (Supplemen-
tal Fig. S4E) and with reduced levels of the elongation
marker H3K36me3 on their gene bodies (Supplemental
Fig. S4E), thereby suggesting that DPY30 knockdown
caused transcriptional impairment. Moreover, SMAD2/3
binding to endoderm genes was also reduced in DPY30
knockdown hESCs differentiated into endoderm (Supple-
mental Fig. S4E). Impaired endoderm specification was
confirmed at the protein level by Western blot and flow
cytometry (Supplemental Fig. S4F,G) and resulted in
the inability of DPY30 knockdown hESCs to further dif-
ferentiate into mature endoderm-derived lineages such
as the liver and pancreas (Fig. 4C). Finally, the impaired
Figure 4. DPY30 is required for mesendoderm differ-
entiation of hESCs. (A) Hematoxylin and eosin histo-
logical staining of normal testis tissue (sham control)
or teratomas derived from DPY30 knockdown (KD) or
control hESCs. (B) Gene expression qPCR in DPY30
knockdown or control hESCs (cells expressing a SCR
shRNA) before (PLURI) or after in vitro directed differ-
entiation toward endoderm or neuroectoderm. For each
gene, significant differences versus both SCR sh1 and
SCR sh2 in the same condition (only the highest P-val-
ue is shown) as calculated by two-way ANOVA are re-
ported. (C ) Gene expression qPCR as in A but either
before (pluripotent [PL]) or after liver (LIV) or pancreas
(PA) differentiation. For each gene, significant differ-
ences versus SCR in the same condition as calculated
by two-way ANOVA are reported. (D) ChIP-qPCR for
H3K4me3 in DPY30 knockdown or control hESCs be-
fore (PLURI) or after endoderm differentiation. Signifi-
cant differences versus SCR sh1 in the same
condition as calculated by two-way ANOVA are
reported.
Activin/Nodal controls H3K4me3 in hESCs
GENES & DEVELOPMENT 709
 Cold Spring Harbor Laboratory Press on May 21, 2015 - Published by genesdev.cshlp.orgDownloaded from 
expression of endoderm markers in DPY30 knockdown
hESCs was associated with decreased H3K4me3 (Fig.
4D), thereby confirming that transcriptional inhibition
provoked by the decrease in DPY30 expression is associat-
ed with epigenetic deregulation.
Overall, these results suggested that loss of H3K4me3
on developmental genes in hESCs impairs their capacity
to differentiate into mesendoderm and thus demonstrate
the functional importance of the correct deposition of
this epigenetic mark for the induction of differentiation
markers and early cell fate decisions.
SMAD2/3 cooperates with NANOG to recruit
H3K4 methyltransferases on Activin/Nodal-
responsive genes
The decrease inDPY30 expression in hESCs not only reca-
pitulated the effects of Activin/Nodal inhibition but also
closely mimicked the consequences of NANOG knock-
down in hESCs (Vallier et al. 2009a). Indeed, NANOG
knockdown impaired the expression of pluripotency
markers and mesendoderm markers while inducing neu-
roectoderm genes (Supplemental Fig. S5A). Furthermore,
microarray analysis demonstrated a significant similarity
between the transcriptional responses toNANOGknock-
down, the inhibition of Activin/Nodal signaling for 48 h,
and DPY30 knockdown (highest hypergeometric P < 1 ×
10−300 and 1 × 10−700, respectively) (Fig. 5A; Supplemental
Table S4; Supplemental Fig. S5B). While these results
were in agreement with the known function of NANOG
as a SMAD2/3 cofactor (Mullen et al. 2011; Teo et al.
2011), they also suggested a previously unknown overlap
between the SMAD2/3–DPY30 and NANOG-dependent
transcriptional networks. Supporting this notion, coim-
munoprecipitation experiments showed that NANOG
could be found in protein complexes containing DPY30
and SMAD2/3 and thatDPY30 and SMAD2/3 coimmuno-
precipitated with NANOG (Fig. 5B; Supplemental Fig.
S5C). Moreover, NANOG knockdown hESCs displayed
lower levels of H3K4me3 on pluripotency and endoderm
genes bound by NANOG and SMAD2/3 (Fig. 5C), further
suggesting a functional linkwith SMAD2/3–DPY30. Con-
sidered together, these results suggest the existence of
a complex between SMAD2/3, NANOG, and DPY30,
which we refer to here as S/N/D.
To further validate this hypothesis, we performed
sequential ChIP experiments that demonstrated that
DPY30 cobinds with both SMAD2/3 and NANOG onto
chromatin regions associated to key regulators of hESC
pluripotency and differentiation (Fig. 5D). We then inves-
tigatedwhether genomic binding ofDPY30 and SMAD2/3
requires the presence of NANOG in the complex. Strik-
ingly, NANOG knockdown impaired binding of both
DPY30 and SMAD2/3 on pluripotency and endoderm
genes (Fig. 5E), suggesting that NANOG could recruit
DPY30 and SMAD2/3 onto its genomic targets. On the
other hand, inhibition of SMAD2/3 binding with 2 h of
SB treatment also resulted in loss of both NANOG and
DPY30 binding (Fig. 5F), indicating that SMAD2/3 was
also necessary for the recruitment of both NANOG and
DPY30. Finally, we evaluated the formation of the S/N/
D complex by coimmunoprecipitation in the presence or
absence of Activin/Nodal signaling (Supplemental Fig.
S5D) or of NANOG expression (Supplemental Fig. S5E).
In both cases, the interaction with DPY30 was impaired,
suggesting that SMAD2/3 phosphorylation and the ex-
pression of NANOG facilitate the assembly of the S/N/
D complex. Taken together, these results implied that
SMAD2/3 andNANOGdepend on each other to efficient-
ly bind Activin/Nodal-responsive genes and recruit
DPY30 on genes characterizing the pluripotent state of
hESCs.
We then investigated whether S/N/D binding correlat-
ed with histone methyltransferase recruitment. First, we
confirmed that COMPASS complexes are recruited in an
Activin/Nodal-dependent manner onto chromatin re-
gions bound by S/N/D, asmeasured byChIP forWDR5 be-
fore and after inhibition of Activin/Nodal signaling for 2 h
(Fig. 5G). Furthermore, we observed that the catalytic sub-
unit MLL2/KMT2B, but not SETD1A or MLL1/KMT2A,
bound to most S/N/D target loci in an Activin/Nodal-de-
pendent manner (Fig. 5G). Accordingly, WDR5 and
MLL2/KMT2B appeared to be part of the S/N/D complex,
as measured by coimmunoprecipitation (Supplemental
Fig. S5C). Interestingly, transient knockdown of DPY30
did not result in impaired recruitment of WDR5 or
MLL2/KMT2B onto S/N/D target regions (Supplemen-
tal Fig. S5F). This observation suggests that the effects
of DPY30 knockdown are the results of impaired
H3K4me3 activity of COMPASS complexes rather than
their impaired recruitment onto the chromatin, in agree-
ment with what was reported in previous studies (Jiang
et al. 2011; Ernst and Vakoc 2012; Yang et al. 2014). Final-
ly, it was recently reported that DPY30 can also be found
in the NURF nucleosome remodeling complex (van
Nuland et al. 2013), and thus we decided to investigate
the binding profile of the NURF catalytic subunit BPTF
on Activin/Nodal target genes. In contrast to the COM-
PASS complexes, BPTF enrichment on S/N/D-bound re-
gions was limited and independent from the presence of
Activin/Nodal signaling (Fig. 5G), arguing against a role
for the NURF complex in the regulation of S/N/D targets.
Overall, these experiments support a model in which
SMAD2/3 and NANOG binding onto Activin/Nodal tar-
get genes induces recruitment of histone methyltransfer-
ases that regulate H3K4me3 deposition (Supplemental
Fig. S5G).
DPY30, NANOG, and SMAD2/3 cooperation is necessary
for H3K4me3 deposition on a core transcriptional
network that characterizes pluripotency
Having established amodel for the functional interactions
between SMAD2/3, NANOG, and DPY30 on a subset of
Activin/Nodal-responsive genes, we decided to extend
our analysis to a genome-wide scale by performing
H3K4me3 ChIP-seq in DPY30 knockdown and NANOG
knockdownhESCs (Supplemental Fig. S6A; Supplemental
Table S5). While both conditions induced a large number
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of significant differences, deregulation of H3K4me3 was
still specific to selected loci: Out of 31,923 peaks in
DPY30 knockdown hESCs, 6482 (20.3%) were decreased,
and 1394 (4.4%) were increased, while 4028 (12.3%) and
1510 (4.6%) of the 32,642 peaks in NANOG knockdown
hESCs were decreased and increased, respectively (Sup-
plemental Fig. S6B; Supplemental Table S5). Interestingly,
regions with decreased H3K4me3 after DPY30 or
NANOG knockdown were associated with genes in-
volved in the development of tissues from all germ layers
(Supplemental Table S5), suggesting a role for DPY30
and NANOG in the regulation of developmental pro-
cesses. Importantly, we observed a large overlap in the
H3K4me3 peaks impaired after DPY30 or NANOG
knockdown, implying that these two factors control a
large set of common genes (2062 peaks using our conser-
vative analysis thresholds: P-value, 1.00 × 10−6; FDR,
0.1%; fold change, >1.5 [Fig. 6A]; and 4071 peaks with
Figure 5. SMAD2/3 and NANOG recruit DPY30 onto their genomic targets. (A) RRHO analysis for genes ranked by their differential
expression after NANOG knockdown (KD), DPY30 knockdown, or inhibition of Activin/Nodal for 48 h with SB. (B) Western blots of
DPY30 or control (IgG) immunoprecipitations (IP) from nuclear extracts of hESCs. Input is 5% of the material used for immunoprecipi-
tation. (C ) ChIP-qPCR for H3K4me3 in NANOG knockdown or control hESCs. For each gene, significant differences versus SCR as cal-
culated by t-test are reported. (D) Sequential ChIP-qPCR forDPY30 followed by SMAD2/3,NANOG, or control (IgG) ChIP. (E) ChIP-qPCR
for the indicated proteins in NANOGknockdown or control hESCs. (F,G) ChIP-qPCR for the indicated proteins in hESCs before and after
inhibition of Activin/Nodal with SB for 2 h. ChIP-qPCR results in D–G are representative of three independent experiments, and the lo-
cation of primers used is shown in Supplemental Figure S5G.
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less stringent thresholds: P-value, 1.00 × 10−4; FDR, 1%;
fold change, >1.25 [Supplemental Fig. S6C]). Nevertheless,
we observed a number of regions specifically affected by
either protein, which was particularly large for DPY30
(4336 and 6209 peaks, respectively, for the two analyses),
in agreement with its general role in promoting the
Figure 6. SMAD2/3, NANOG, and DPY30 control H3K4me3 on a subset of shared genes. (A) Overlap between H3K4me3 peaks signifi-
cantly down-regulated after DPY30 knockdown (KD) and NANOG knockdown. (B) The proportion of H3K4me3 peaks significantly
down-regulatedafter2 hofActivin/Nodal inhibitionwithSBthatwerealsosimilarlyaffectedbyDPY30knockdown,NANOGknockdown,
orbothtreatments.Representativegenesassociated topeaksdown-regulated inall conditionsarereported. (C ) ExamplesofChIP-seqresults
for H3K4me3 on selected SMAD2/3 target genes before or after DPY30 knockdown, NANOG knockdown, or SB treatment for 2 h. Lines
represent read enrichment normalized by million mapped reads and the size of the library. (D) Expression of the genes closest to
H3K4me3 peaks significantly down-regulated by >50% after both DPY30 knockdown and NANOG knockdown but not decreased to the
same extent after 2 h of SB. The significance of expression differences versusActivin as calculated byWelch’s t-test is reported. (E) Average
normalizedH3K4me3 readenrichment in threebiological replicates before or after 2hof SB.Data refer only toH3K4me3peaksdescribed in
D. The level of significant changeversusActivin as calculatedusingWelch’s t-test is reported. (F ) ChIP-qPCR forH3K4me3before and after
inhibition SB for 2, 4, 8, or 48 h. The genes analyzed belong to the group described inD. For each gene, significant changes versusActivin as
calculatedbyone-wayANOVAarereported. (G)ExamplesofChIP-seqcoverage(top)andpeaks(bottom) forSMAD2/3,NANOG,andDPY30
inhESCs. (H) Heatmaps of coverage for SMAD2/3,NANOG, andDPY30ChIP-seq relative to the SMAD2/3peaks located 100kbupstream
of/downstream fromH3K4me3 regions decreased after 2 h of SB (530 peaks). (I ) Mean coverage plots for the peaks considered inH.
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activity of COMPASS complexes (Jiang et al. 2011). These
observations demonstrated that NANOG and DPY30 are
required tomaintainH3K4me3 on a large but specific sub-
set of genomic regions involved in early cell fate decisions.
Interestingly, a large proportion (44%) of H3K4me3
peaks decreasing after 2 h of SB significantly overlapped
with those decreasing after both NANOG and DPY30
knockdown (Fig. 6B, overlap Z-score of 30.63, P = 4.11 ×
10−206, as calculated with MULTOVL; see also Supple-
mental Fig. S6D for the same analysis with less stringent
thresholds: P-value, 1.00 × 10−4; FDR 1%; fold change,
>1.25). These regions were associated to genes that in-
clude the key pluripotency markers NANOG, POU5F1/
OCT4, DPPA4, and PRDM14 and the mesendoderm
regulators LEFTY1, WNT3, CER1, FGF8 , and NODAL
(Fig. 6C). Therefore, while the long-term knockdown of
NANOG and DPY30 induces a larger H3K4me3 deregula-
tion compared with the one resulting from 2 h of inhibi-
tion of Activin/Nodal signaling, there appears to be a
core set of crucial genes that are directly controlled by
SMAD2/3, NANOG, and DPY30.
On the other hand, the large number of H3K4me3 peaks
that decreased by >50%after bothDPY30 knockdown and
NANOG knockdown but not after 2 h of SB (1847 peaks)
could be controlled independently of SMAD2/3. Howev-
er, the expression of several of these genes was signifi-
cantly impaired after 48 h of inhibition of Activin/Nodal
signaling with SB (Fig. 6D), arguing against a SMAD2/3-
independent regulation. Furthermore, there was still a
significant decrease in H3K4me3 after SB for 2 h on these
genomic regions (Fig. 6E), but this effect was not uncov-
ered by our previous analysis, which filtered results for
only major modifications (>50%). The observation that
H3K4me3 of these regions was modestly affected after
2 h of SB suggested that they might represent a class of
genes that have a slower kinetics of H3K4me3 loss. This
was supported by ChIP-qPCR for several such genes
showing that the decrease of H3K4me3 reached its
maximum only after 48 h of Activin/Nodal inhibition
(Fig. 6F). In conclusion, there is a large number of genes
where H3K4me3 is controlled by SMAD2/3, DPY30, and
NANOG, but the full histone demethylation on these tar-
gets occurs in a slow fashion and only after chronic inhibi-
tion of Activin/Nodal.
In addition to H3K4me3, we also performed ChIP-seq
for H3K27me3 after DPY30 knockdown or NANOG
knockdown (Supplemental Fig. S6A,B; Supplemental Ta-
ble S5). In sharp contrast to the results from treatment
with SB for 2 h, we identified many regions of differential
H3K27me3 (2669 decreased and 2240 increased regions
out of 12,728 peaks for DPY30 knockdown; 4580 de-
creased and 3333 increased regions out of 16,152 peaks
for NANOGknockdown).Moreover, the regions in which
H3K27me3 changed after DPY30 orNANOGknockdown
did not show any significant difference in the H3K27me3
levels after 2 h of SB (Supplemental Fig. S6E). These data
implied that this repressive histone mark required more
time to change when compared with H3K4me3. This sug-
gests that Activin/Nodal signaling might not be directly
involved in the regulation of H3K27me3 in hESCs, while
NANOG and DPY30 could have a more important role in
this process. In summary, these results confirmed and val-
idated a model in which SMAD2/3, NANOG, and DPY30
collaborate to maintain H3K4me3 on a subset of genes,
which can be divided into two classes defined by the speed
atwhich they loseH3K4me3, thereby suggesting an epige-
netic hierarchy between different regulators of cell fate
decisions.
DPY30, NANOG, and SMAD2/3 colocalize
at the genome-wide level
We next decided to investigate whether the functional
interactions described above could imply collaborative
mechanisms between SMAD2/3, NANOG, and DPY30
at a genome-wide level. For that, we performed ChIP-seq
for DPY30 on control (SCR shRNA) hESCs and DPY30
knockdown hESCs. These analyses revealed that DPY30
could be found on 26,387 genomic regions in hESCs,
while only 6893 peaks were identified in DPY30 knock-
down hESCs (Supplemental Table S5). Moreover, DPY30
ChIP-seq coverage was strongly impaired in DPY30
knockdown hESCs comparedwith control hESCs (Supple-
mental Fig. S6F,G). Finally, DPY30 binding correlated
with H3K4me3 deposition, as expected and previously
shown for mESCs (Supplemental Fig. S6F; Jiang et al.
2011). Overall, these findings confirmed the specificity
of the DPY30 antibody and validated the quality of the
DPY30 ChIP-seq. We then combined this data set with
pre-existing ChIP-seq analyses for SMAD2/3 (Brown
et al. 2011) and NANOG (ENCODE data) (Bernstein
et al. 2012). Interestingly, a large proportion of genome-
wide binding sites of SMAD2/3 were co-occupied by
both NANOG and DPY30 read enrichment (Supplemen-
tal Fig. S6H,I). Of note, the colocalization of SMAD2/3
and NANOG is in agreement with previous reports (Mul-
len et al. 2011), while our data suggest that DPY30 is also
present in this complex. Interestingly, NANOG- and
DPY30-binding sites overlapped or were closely associat-
ed to SMAD2/3-binding sites located on key genes on
which H3K4me3 is decreased after 2 h of SB (Fig. 6G). Fur-
thermore, NANOG and DPY30 extensively co-occupied
SMAD2/3-binding sites associated with H3K4me3 re-
gions responsive to Activin/Nodal signaling (located 100
kb upstream/downstream, as described earlier) (Fig. 6H),
and the extent of NANOG and DPY30 enrichment on
such regions was even higher than what was observed ge-
nome-wide on all SMAD2/3-binding sites (Fig. 6I; Supple-
mental Fig. S6I). Overall, these findings demonstrated that
SMAD2/3, NANOG, and DPY30 can be found in close
proximity at the genome-wide level, thereby reinforcing
our hypothesis that these factors form a complex control-
ling H3K4me3 deposition on target genes regulated by
Activin/Nodal signaling.
Dpy30 is necessary to maintain the pluripotent
state of the post-implantation epiblast
To confirm the relevance of the mechanisms uncovered
by our studies in vitro,we decided to evaluate the function
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of Dpy30 during embryonic development in mice. For
that, we took advantage of Dpy30 knockoutmice generat-
ed by the Mouse Genetic Program of the Wellcome Trust
Sanger Institute [Dpy30<tm1a(KOMP)Wtsi>] (Supple-
mental Fig. S7A–C). Mice carrying heterozygous muta-
tions were healthy, and we did not observe any obvious
phenotype. However, viable homozygous mutant mice
could never be recovered, and further analysis revealed
that the absence of Dpy30 was embryonic-lethal between
embryonic day 7.5 (E7.5) and E9.5 (Fig. 7A). In addition,
mutant embryos recovered at E6.5 displayed gross mor-
phological abnormalities, including reduced size and no
clear anterior–posterior patterning, as marked by the ab-
sence of the primitive streak (Fig. 7B). Accordingly,
Dpy30 knockout embryos at E7.5 were developmentally
delayed and underwent resorption (Fig. 7B). Importantly,
the absence of Dpy30 expression in homozygous mutant
embryos was confirmed by qPCR to validate the gene tar-
geting strategy (Supplemental Fig. S7D).Moreover, Dpy30
knockout embryos dissected at E6.5 showed prematurely
reduced expression of epiblast markers (Nanog and
Pou5f1/Oct4) and failed to properly induce mesendoderm
genes (Eomes,Gsc, and Brachyury), while neuroectoderm
markerswere either unaffected (Sox2 and Sox1) or even in-
creased (Dlx5 andHesx1) (Fig. 7C). Therefore, we conclud-
ed that Dpy30 is necessary to maintain the pluripotent
state of the epiblast of the post-implantation embryo
and also enable proper specification of the three germ lay-
ers in vivo. These results strikingly recapitulate the phe-
notype induced by the knockdown of DPY30 in hESCs,
indicating that the molecular regulations that we uncov-
ered in vitro could also occur at the corresponding devel-
opmental stage during early embryogenesis (Fig. 7D).
Discussion
Here we uncovered the mechanisms by which extracellu-
lar signals are converted into epigenetic and transcription-
al regulations necessary for hESC pluripotency and cell
fate decisions. The effectors of the Activin/Nodal signal-
ing pathway SMAD2/3 and NANOG recruit DPY30-con-
taining COMPASS complexes onto specific genomic
regions where they maintain H3K4me3. This event is es-
sential to maintain the expression of a core set of factors
necessary for pluripotency. Accordingly, inhibition of
Activin/Nodal signaling results in a rapid decrease in
bothH3K4me3andexpressionof severalmaster regulators
Figure 7. Dpy30 is required for mouse post-implantation embryonic development. (A) Genotyping results from Dpy30 mutant hetero-
zygous crosses. Stages are embryonic (E) or postnatal (P) days. (B) Bright-field images of wild-type (+/+) orDpy30 knockout (−/−) embryos at
E6.5 or E7.5. The anterior–posterior (A/P) and proximal–distal (PR/D) axes are shown. Bars, 100 μm. (C ) Gene expression qPCR in E6.5
embryos fromDpy30mutant heterozygous crosses. Note that Sox2 is both an epiblast and a neuroectodermmarker. Significant differenc-
es versus Dpy30+/+ as calculated by one-way ANOVA are reported. n = 6 for Dpy30+/+ and Dpy30−/−; n = 11 for Dpy30+/−. (D) Schematic of
themodel that we propose for Activin/Nodal-dependent transcriptional regulation of pluripotency andmesendoderm genes in hESCs and
mouseepiblast cells.Note that the interactions depicted in themodelmust be interpreted as functional ones rather thandirectprotein–pro-
tein interactions, as this aspect was not the focus of the present study.
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of hESC pluripotency, includingNANOG itself. NANOG
is involved in a feed-forward regulatory network that
maintains its own expression and that of other core pluri-
potency factors, such as OCT4, all of which are part of a
broader SMAD2/3-dependent transcriptional network
characterizing hPSCs (Mullen et al. 2011; Teo et al.
2011). As such, the quick loss of H3K4me3 upon Acti-
vin/Nodal inhibition provides hESCs with an extremely
rapid way to switch off the expression of master pluripo-
tency regulators, including NANOG. This mechanism
initiates a cascade of transcriptional network modifica-
tions necessary for timely and efficient cell fate decisions.
Our data show that MLL2/KMT2B could be the COM-
PASScomplexregulatingabroadpartof the transcriptional
network downstream from Activin/Nodal signaling. In-
terestingly, MLL2/KMT2B was reported to regulate
H3K4me3 on bivalent promoters in mESCs (Hu et al.
2013; Denissov et al. 2014). Nonetheless, we cannot ex-
clude that other COMPASS complexes are involved in
these regulations in hESCs, and further investigation will
be necessary to explore this possibility. Similarly, addi-
tional epigeneticmodifiers could be involved in the regula-
tionsuncoveredbyourstudy, sinceDPY30hasbeenshown
to also interactwith theNURF complex (vanNuland et al.
2013). However, we could not detect any signaling-depen-
dent binding event of theNURF complex onActivin/Nod-
al genes, suggesting that the activity of this complex is not
directly relevant for the mechanisms discussed here.
Interestingly, the prompt and selective decrease of
H3K4me3 on pluripotency genes upon signaling inhibi-
tion suggests the existence of an active process to erase
positive histone marks on these specific genomic regions.
Likely candidates for such a role are the H3K4-specific
histone demethylases of the JARID1 family. Indeed, the
profile of histone methylation after inhibition of Acti-
vin/Nodal signaling is consistent with the sequential
H3K4me3 and H3K4me2 demethylation that is known
to be mediated by this class of demethylases (Cloos
et al. 2008). Interestingly, knockdown in Jarid1B expres-
sion in mESCs impairs silencing of pluripotency genes
and differentiation into neuroectoderm (Schmitz et al.
2011). Therefore, the epigenetic status of a core pluripo-
tency network could be tightly controlled by extracellular
signals through the dynamic competition of histone
methylation writers and erasers.
Our results also show thatActivin/Nodal signaling con-
trols H3K4me3 presence on “bivalent genes” known to be
master regulators of mesendoderm specification. Inhibi-
tion of Activin/Nodal, NANOG knockdown, and
DPY30 knockdown are all associated with a decrease of
H3K4me3 on these loci, which correlates with an im-
paired capacity of hESCs to differentiate towardmesendo-
derm. These results suggest that positive marks are
maintained by active mechanisms on key bivalent genes
and that the deposition of thesemarks could be indispens-
able for proper induction of differentiation. This supports
the hypothesis that bivalent marks are necessary to poise
developmental genes for efficient and synchronous cell
fate decisions in response to extracellular signaling (Bern-
stein et al. 2006; Vastenhouw and Schier 2012).
Importantly, our study suggests that the presence of
H3K4me3 on Activin/Nodal target genes not only is a
consequence of the level of transcription but might also
be a causal event that directly influences gene expression.
Indeed, knockdown of the epigenetic remodeler DPY30 is
sufficient to mimic the transcriptional effect of Activin/
Nodal inhibition. Several epigenetic readers are known
to link H3K4me3 with various factors that can promote
gene expression, including TFIID, SAGA, NuRF/BPTF,
and Sin3B/HDAC complexes (Vermeulen et al. 2010).
Thus, it is tempting to assume that H3K4me3 deposition
could control transcription trough these interactions.
However, in-depth functional analyses will be necessary
to confirm this hypothesis linking loss of H3K4me3 and
decreased transcription of Activin/Nodal target genes in
hESCs.
The role of H3K4me3 in pluripotency and differentia-
tion has been a matter of open controversy (Vastenhouw
and Schier 2012; Voigt et al. 2013). Studies in mESCs
showed that knockdown of Dpy30 or Rbbp5 impairs
only differentiation without affecting the expression of
pluripotency genes, while knockdown of Wdr5 results in
dramatic loss of self-renewal (Ang et al. 2011; Jiang et al.
2011). These diverging results might arise from either
different levels of H3K4me3 impairment or the known
pleiotropic functions ofWdr5 (vanNuland et al. 2013). Im-
portantly, these studies were limited to in vitro experi-
ments in mESCs and hence did not test the relevance of
H3K4me3 during in vivo development or provide evi-
dence for an evolutionarily conserved role of H3K4me3
across mice and humans. Our study addresses both of
these aspects: By combining both experiments in hESCs
and in vivo analyses in mice, we demonstrated an evolu-
tionarily conserved fundamental role of H3K4me3 in plu-
ripotency and cell fate decisions. The divergent function
of DPY30 in hESCs and mESCs can be explained by their
different embryonic identities. Indeed, hESCs are pheno-
typically related to the PSCs of the post-implantation epi-
blast, while mESCs resemble cells of the inner cell mass
(ICM) (Brons et al. 2007; Vallier et al. 2009c). This hypoth-
esis is supported by our genetic study in mice showing
that Dpy30 is essential only for post-implantation devel-
opment and gastrulation of the epiblast. Thus,
H3K4me3 deposition could be of prominent importance
specifically during the establishment of the epiblast,
when Activin/Nodal signaling starts to orchestrate the
core pluripotency network. It is also worth highlighting
that the Dpy30 knockout mouse phenotype closely reca-
pitulates the one of embryos mutant for Nodal or
Smad2/3 (Brennan et al. 2001; Camus et al. 2006). Indeed,
the absence of Nodal signaling results in the loss of pluri-
potency markers in the epiblast, impaired gastrulation,
and ectopic expression of neuroectodermmarkers. There-
fore, epigenetic control imposed by Activin/Nodal signal-
ing in hESCs is also taking place in the late epiblast during
embryonic development. Overall, our results show that
the function of epigenetic modifiers can significantly dif-
fer in the pre- and post-implantation pluripotent embryos
and thus should be carefully evaluated using different
Activin/Nodal controls H3K4me3 in hESCs
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types of PSCs that resemble these different developmental
stages.
The interconnection between Activin/Nodal signaling
and SMAD2/3-dependent deposition of H3K4me3 on
master regulators of cell fate could be relevant for many
cell types. Indeed, TGFβ is a widespread pathway (Mas-
sagué 2012), andH3K4me3 is a histonemark that is depos-
ited in virtually any cell type (Ruthenburg et al. 2007). Of
particular interest, TGFβ signaling regulates the balance
between self-renewal and differentiation of several adult
stem cells as well as many cancer stem cells (Caja et al.
2012). Thus, our findings not only reveal the mechanisms
that coordinate Activin/Nodal signaling with epigenetic
and transcriptional networks during early cell fate deci-
sions of hESCs but also establish general principles that
can be applicable to stem cells involved in human devel-
opment and disease.
Materials and methods
hESC culture, differentiation, and characterization
Feeder-free H9 hESCs (WiCell) were grown in chemically defined
culture mediumwith 10 ng/mL Activin A and 12 ng/mL FGF2 as
described in Brons et al. (2007). The formulation of all cell culture
media and reagents is reported inSupplementalTable S6.Activin/
Nodal inhibition was performed by replacing Activin A with 10
μM SB. hESCs were differentiated into endoderm for 3 d in
CDM-PVA with 20 ng/mL FGF2, 10 μM Ly-294002, 100 ng/mL
Activin A, and 10 ng/mL BMP4, while neuroectoderm differenti-
ationwas induced for 6 d in CDMwith 12 ng/mL FGF2 and 10 μM
SB (Vallier et al. 2009b). Pancreatic and hepatic specification was
initiated after endodermdifferentiation, anddetails of thesediffer-
entiation protocols can be found in Supplemental Table S6. Tera-
tomas were induced by injection of 1 million hESCs into the
testicular lumen of SCIDmice and analyzed after 12wk by hema-
toxylinandeosin staining.Transient and stableknockdownswere
performed using pLKO.1 plasmids with specific shRNAs trans-
fected with Lipofectamine 2000 as described in Teo et al. (2011).
Gene and protein expression analysis
Standard methods for qPCR, immunostaining, Western blot, and
flow cytometry were previously described (Vallier et al. 2009b;
Pauklin and Vallier 2013), and details on primers and antibodies
used are in Supplemental Table S6. GraphPad Prism 5 was used
for statistical analysis. One-way or two-way ANOVA tests were
followed by Bonferroni’s corrected multiple comparisons be-
tween pairs of conditions. Unless otherwise indicated in the fig-
ure legends, we analyzed three biological replicates for each
data point in all graphs, and the level of significance was as fol-
lows: P < 0.05 (∗), P < 0.01 (∗∗), and P < 0.001 (∗∗∗).
Immunoprecipitation and ChIP
Immunoprecipitation and ChIP and were performed as described
previously in Brown et al. (2011) and Pauklin and Vallier (2013),
and details on protocols, reagents, antibodies, and genomic prim-
ers are reported in the Supplemental Material and Supplemental
Table S6. ChIP-qPCR data were normalized on a negative control
region (transcription factor ChIP) or the amount of input DNA
(histonemarkChIP). Sequential ChIPwas performed as described
in Truax and Greer (2012) with minor modifications as described
in the Supplemental Material.
Microarrays
Microarrays were performed on biological triplicates using Illu-
mina HT12-v4.0 bead chips, and the raw data were processed us-
ing Genome Studio (Illumina) and normalized using the R/
Bioconductor package lumi. The raw and processed microarray
data are available on ArrayExpress (E-MTAB-2749). Microarray
bioinformatic analyses are described in the Supplemental
Material.
ChIP-seq
ChIP sampleswere sequenced using IlluminaHiSeq 2000, and the
raw data are publicly available on ArrayExpress (E-ERAD-191:
histone mark ChIP-seq; E-ERAD-365: DPY30 ChIP-seq). ChIP-
seq bioinformatic analyses are described in the Supplemental
Material.
Generation and phenotyping of Dpy30 knockout mice
All animal procedures were performed in agreement with the
United Kingdom Home Office regulations, United Kingdom An-
imals (Scientific Procedures) Act of 1996. Dpy30 knockout mice
were generated by the Sanger Institute Mouse Genetics Project.
Dysmorphology assessments were performed on embryos dis-
sected from the decidua of pregnant females after removal of ex-
traembryonic tissues, and qPCR analyses were done on RNA
extracted from individual embryos.
Detailed descriptions and additional references for all the ex-
perimental and bioinformatics procedures presented here are pro-
vided in the Supplemental Material.
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